PT  - JOURNAL ARTICLE
AU - Nightingale Health Biobank Collaborative Group
AU  - Barrett, Jeffrey C.
AU  - Esko, Tõnu
AU  - Fischer, Krista
AU  - Jostins-Dean, Luke
AU  - Jousilahti, Pekka
AU  - Julkunen, Heli
AU  - Jääskeläinen, Tuija
AU  - Kerimov, Nurlan
AU  - Kerminen, Sini
AU  - Kolde, Anastassia
AU  - Koskela, Harri
AU  - Kronberg, Jaanika
AU  - Lundgren, Sara N.
AU  - Lundqvist, Annamari
AU  - Mäkelä, Valtteri
AU  - Nybo, Kristian
AU  - Perola, Markus
AU  - Salomaa, Veikko
AU  - Schut, Kirsten
AU  - Soikkeli, Maiju
AU  - Soininen, Pasi
AU  - Tiainen, Mika
AU  - Tillmann, Taavi
AU  - Würtz, Peter
AU - the Estonian Biobank Research Team
TI  - Metabolomic and genomic prediction of common diseases in 477,706 participants in three national biobanks
AID  - 10.1101/2023.06.09.23291213
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.09.23291213
4099  - http://medrxiv.org/content/early/2023/06/12/2023.06.09.23291213.short
4100  - http://medrxiv.org/content/early/2023/06/12/2023.06.09.23291213.full
AB  - Identifying individuals at high risk of chronic diseases via easily measured biomarkers could improve public health efforts to prevent avoidable illness and death. Here we present nuclear magnetic resonance blood metabolomics from half a million samples from three national biobanks. We built metabolomic risk scores that identify a high-risk group for each of 12 diseases that cause the most morbidity in high-income countries and show consistent cross-biobank replication of the relative risk of disease for these groups. We show that these metabolomic risk scores are more strongly associated with future disease onset than polygenic scores for most of these diseases. In a subset of 18,000 individuals with metabolomic biomarkers measured at two time points we show that people whose scores change have dramatically different future risk of disease, suggesting that repeat measurements capture the benefits of lifestyle change. We show cross-biobank calibration of our scores. Since metabolomics can be measured from a standard blood sample, we propose such tests can be feasibly implemented today in preventative health programs.One-Sentence Summary Biomarkers from half a million blood samples identifies people at increased risk of chronic diseases and can be used for early detection today.Competing Interest StatementAuthors affiliated with Nightingale Health are employees of, and own shares or stock options in, that company.Funding StatementThis study was funded by Nightingale Health Plc. Estonian Biobank was supported by Estonian Research Council grant PRG1291. UK Biobank funding is described at https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/our-funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper describes analysis of samples from three national biobanks (in Finland, Estonia, and the UK): UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC). Estonian Biobank has approval from the ethics committee of the Estonian eHealth Foundation. THL Biobanks have approval from the Finnish National Committee on Medical Research EthicsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe Nightingale Health NMR biomarker data for 300,000 individuals are released to the UK Biobank resource in July 2023 (https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220). The UK Biobank data are available for approved researchers through the UK Biobank data-access protocol (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). Data from Estonia Biobank can be accessed through a research application to Institute of Genomics of the University of Tartu (https://genomics.ut.ee/en/content/estonian-biobank). Data from FINRISK and Health 2000 cohorts can be accessed through a research application to THL Biobank (https://thl.fi/en/web/thl-biobank). https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=220 https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access https://genomics.ut.ee/en/content/estonian-biobank https://thl.fi/en/web/thl-biobank